Skip to main content

Table 1 Summary of patient demographics and Braak staging of AD-tau

From: Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)

  CBD
N = 49
PSP
N = 109
PiD
N = 22
Sex M = 19 M = 69 M = 13
F = 30 F = 40 F = 9
Age at death (years) 67.5 (9.5) 76 (71, 81)a 67 (61, 74)
Age at onset (years) 61.6 (9.3) 67 (62,74)a 57.8 (11.1)
Disease duration (years) 6.0 (2.5) 7 (4, 10)b 9.0 (4.0)
PMI (hours) 11 (5, 17) 12 (6, 19) 12.5 (7, 20)
Brain weight (g) 1139 (139) 1213 (1121, 1304)a 1026 (161)
Clinical phenotype CBS = 18 PSP-RS = 61 CBS = 2
PSP = 12 PSP-SL = 6 PPA = 1
PPA = 9 PSP-CBS = 8 bvFTD-FTLD = 8
bvFTD-FTLD = 3 PSP-F = 14 FTD-NOS = 10
FTD- NOS = 4 PSP-P = 8 DLB = 1
AD = 1 PSP-PGF = 1  
DLB = 1 Other cognitive = 8  
Undetermined = 1 Other motor = 3  
APOE haplotype E2/E2 = 0 E2/E2 = 2 E2/E2 = 1
E2/E3 = 8 E2/E3 = 16 E2/E3 = 1
E2/E4 = 0 E2/E4 = 5 E2/E4 = 0
E3/E3 = 33 E3/E3 = 63 E3/E3 = 16
E3/E4 = 7 E3/E4 = 12 E3/E4 = 3
E4/E4 = 1 E4/E4 = 3 E4/E4 = 0
N/A = 0 N/A = 8 N/A = 1
CERAD 0 = 31 0 = 53 0 = 17
1 = 9 1 = 15 1 = 1
2 = 3 2 = 14 2 = 1
3 = 2 3 = 17 3 = 2
N/A = 4 N/A = 10 N/A = 1
Thal phase 0 = 27 0 = 37 0 = 14
1 = 16 1 = 32 1 = 3
2 = 3 2 = 21 2 = 4
3 = 3 3 = 16 3 = 1
N/A = 0 N/A = 3 N/A = 0
Braak stage B0 = 24 B0 = 28 B0 = 13
B1 = 21 B1 = 50 B1 = 7
B2 = 4 B2 = 25 B2 = 1
B3 = 0 B3 = 6 B3 = 1
AD Neuropathological change Not = 27 Not = 38 Not = 14
Low = 19 Low = 50 Low = 7
Intermediate = 3 Intermediate = 15 Intermediate = 0
High = 0 High = 4 High = 1
  1. Variables with normal distribution are reported as mean (standard deviation) and variables that are non-normally distributed are reported as median (first quartile, third quartile)
  2. PMI post mortem interval from death to autopsy, CERAD consortium to establish a registry for Alzheimer’s disease, CBS corticobasal syndrome, PPA primary progressive aphasia, bvFTD-FTLD behavioral variant frontotemporal dementia – frontotemporal lobar degeneration, DLB dementia with Lewy bodies, FTD-NOS frontotemporal dementia not otherwise specified, RS Richardson’s syndrome, SL speech and language disorders, F frontal lobe cognitive or behavioral presentation, P Parkinsonism, PGF progressive gait freezing, N/A not available
  3. ap < 0.01 difference between PSP and CBD and PiD
  4. bp < 0.05 difference between PSP and CBD and PiD